207 related articles for article (PubMed ID: 34158341)
1. Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development.
Gill SJ; Wijnhoven PWG; Fok JHL; Lloyd RL; Cairns J; Armenia J; Nikkilä J; Lau A; Bakkenist CJ; Galbraith SM; Vens C; O'Connor MJ
Mol Cancer Ther; 2021 Sep; 20(9):1614-1626. PubMed ID: 34158341
[TBL] [Abstract][Full Text] [Related]
2. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Mao Y; Huang X; Shuang Z; Lin G; Wang J; Duan F; Chen J; Li S
Cancer Med; 2018 Apr; 7(4):1285-1296. PubMed ID: 29479816
[TBL] [Abstract][Full Text] [Related]
4. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
5. The combination of olaparib and camptothecin for effective radiosensitization.
Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Riches LC; Trinidad AG; Hughes G; Jones GN; Hughes AM; Thomason AG; Gavine P; Cui A; Ling S; Stott J; Clark R; Peel S; Gill P; Goodwin LM; Smith A; Pike KG; Barlaam B; Pass M; O'Connor MJ; Smith G; Cadogan EB
Mol Cancer Ther; 2020 Jan; 19(1):13-25. PubMed ID: 31534013
[TBL] [Abstract][Full Text] [Related]
8. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
9. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
[TBL] [Abstract][Full Text] [Related]
10. Olaparib nanoparticles potentiated radiosensitization effects on lung cancer.
Wu M; Liu J; Hu C; Li D; Yang J; Wu Z; Yang L; Chen Y; Fu S; Wu J
Int J Nanomedicine; 2018; 13():8461-8472. PubMed ID: 30587971
[TBL] [Abstract][Full Text] [Related]
11. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Verhagen CV; de Haan R; Hageman F; Oostendorp TP; Carli AL; O'Connor MJ; Jonkers J; Verheij M; van den Brekel MW; Vens C
Radiother Oncol; 2015 Sep; 116(3):358-65. PubMed ID: 25981132
[TBL] [Abstract][Full Text] [Related]
12. ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.
Nam AR; Yoon J; Jin MH; Bang JH; Oh KS; Seo HR; Kim JM; Kim TY; Oh DY
Cancer Lett; 2021 Sep; 516():38-47. PubMed ID: 34082024
[TBL] [Abstract][Full Text] [Related]
13. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
14. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
15. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Fok JHL; Ramos-Montoya A; Vazquez-Chantada M; Wijnhoven PWG; Follia V; James N; Farrington PM; Karmokar A; Willis SE; Cairns J; Nikkilä J; Beattie D; Lamont GM; Finlay MRV; Wilson J; Smith A; O'Connor LO; Ling S; Fawell SE; O'Connor MJ; Hollingsworth SJ; Dean E; Goldberg FW; Davies BR; Cadogan EB
Nat Commun; 2019 Nov; 10(1):5065. PubMed ID: 31699977
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
[TBL] [Abstract][Full Text] [Related]
17. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
18. Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons.
Bright SJ; Flint DB; Martinus DKJ; Turner BX; Manandhar M; Ben Kacem M; McFadden CH; Yap TA; Shaitelman SF; Sawakuchi GO
Radiat Res; 2022 Oct; 198(4):336-346. PubMed ID: 35939823
[TBL] [Abstract][Full Text] [Related]
19. Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells.
Faulhaber EM; Jost T; Symank J; Scheper J; Bürkel F; Fietkau R; Hecht M; Distel LV
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34204447
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
Lee TW; Wong WW; Dickson BD; Lipert B; Cheng GJ; Hunter FW; Hay MP; Wilson WR
Int J Radiat Biol; 2019 Dec; 95(12):1597-1612. PubMed ID: 31490091
[No Abstract] [Full Text] [Related]
[Next] [New Search]